LINC01348: A Non-protein Coding RNA Molecule as A Drug Target Or Biomarker

Target Name: LINC01348

NCBI ID: G731656

LINC01348

Other Name(s): Long intergenic non-protein coding RNA 1348 | long intergenic non-protein coding RNA 1348

LINC01348: A Non-protein Coding RNA Molecule as A Drug Target Or Biomarker

LINC01348 is a non-protein coding RNA (ncRNA) molecule that has been identified using RNA sequencing (RNA-seq) experiments. It is a transcribed RNA molecule that comes from the non-coding regions of the genome.

RNA-seq is a technique that allows researchers to identify and quantify the expression levels of RNA molecules in a given sample. By analyzing the expression levels of RNA molecules, researchers can gain insights into the functions and processes of the cells or organisms in question.

One of the challenges in analyzing RNA-seq data is identifying known RNA molecules that have been expressed in the sample. This is because many RNA molecules are produced by gene transcription, but they may not be well-characterized or may have multiple isoforms. To To overcome this challenge, researchers use a variety of techniques, such as bioinformatic analysis and cell-based assays, to identify potential candidates for drug targets or biomarkers.

LINC01348 is one of the potential candidates identified using RNA-seq experiments. It has been shown to be expressed in a variety of tissues and cells, including brain, heart, and muscle. Additionally, studies have suggested that LINC01348 may be involved in a variety of cellular processes, including cell signaling, cell growth, and DNA replication.

One potential reason why LINC01348 may be a drug target is its involvement in cell signaling. LINC01348 has been shown to be involved in the regulation of several cellular processes, including cell adhesion, migration, and the formation of neural synapses. Additionally, studies have suggested that LINC01348 may be involved in the regulation of cellular responses to external stimuli, such as changes in temperature or pH.

Another potential reason why LINC01348 may be a drug target is its involvement in cancer. LINC01348 has been shown to be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, studies have suggested that LINC01348 may be involved in the regulation of cellular processes that are commonly associated with cancer, such as cell proliferation and apoptosis.

In addition to its potential role in drug targeting, LINC01348 has also been identified as a potential biomarker. Its expression has been shown to be associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, studies have suggested that LINC01348 may be involved in the regulation of cellular processes that are commonly associated with these diseases, such as inflammation and immune cell function.

Overall, LINC01348 is a promising candidate for drug targeting or biomarker research. Further studies are needed to fully understand its functions and properties, and to determine its potential as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1348

The "LINC01348 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01348 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets